HasenTech is a pioneering biotech company leading the way in the use of bacterial products to revolutionize the way we treat and prevent inflammatory diseases. Our innovative approach is based on ground-breaking research that has identified an exopolysaccharide (EPS) from the commensal microbe B. subtilis that provides protection from multiple inflammatory diseases in mice, including inflammatory bowel disease (IBD) and graft versus host disease (GVHD).
Our current work, supported by a prestigious NIH STTR grant, is focused on taking this cutting-edge research to the next level by demonstrating the efficacy of EPS in treating a humanized mouse model of GVHD, and exploring additional applications of cell-based therapies to treat a range inflammatory and autoimmune diseases and conditions.
With a deep commitment to innovation and an experienced leadership team with a long an productive history of working together in translational immunology, HasenTech is at the forefront of the fight against debilitating and life-threatening inflammatory diseases.
Our current work, supported by a prestigious NIH STTR grant, is focused on taking this cutting-edge research to the next level by demonstrating the efficacy of EPS in treating a humanized mouse model of GVHD, and exploring additional applications of cell-based therapies to treat a range inflammatory and autoimmune diseases and conditions.
With a deep commitment to innovation and an experienced leadership team with a long an productive history of working together in translational immunology, HasenTech is at the forefront of the fight against debilitating and life-threatening inflammatory diseases.